Drug Trial Radar · NCT07876674
A Phase III Clinical Trial Evaluating SR604 Injection for Prophylactic Treatment in Patients With Hemophilia
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Sep 30, 2026
Primary completion
Sep 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Shanghai RAAS Blood Products Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, multicenter Phase III clinical trial designed to evaluate the efficacy and safety of prophylactic treatment with SR604 Injection in hemophilia A/B patients with or without inhibitors.
Conditions
- Hemophilia A
- Hemophilia A and B
- Hemophilia B
Interventions
SR604Drug
SR604 will be administered as SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treated total annualized bleeding rate (ABR) over 28 weeks of treatmentTime frame: Through week 28
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.